US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

24.32

-0.1800-0.73%

Post-market: 23.97-0.3500-1.44%19:56 EDT

Volume:25.81K

Turnover:629.58K

Market Cap:56.42M

PE:- -

High:24.66

Open:24.66

Low:24.14

Close:24.50

52wk High:27.02

52wk Low:15.63

Shares:2.32M

Float Shares:2.32M

Volume Ratio:0.54

T/O Rate:1.11%

Dividend:1.71

Dividend Rate:7.01%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating

MT Newswires Live

Praxis Precision Q2 Net Loss Widens on Higher Expenses

Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs

GH Research Plc Q2 EPS USD -0.23

THOMSON REUTERS

GH Research Says H1 Loss Widens as R&D Spending Rises on GH001 Clinical, Technical Development Work

Scholar Rock Q2 Net Loss Narrows

GH Research Publishes Corporate Presentation on Ultra-Rapid, Durable Remission Data for TRD Treatment GH001

GH Research Q2 FY26 Net Loss Widens to $15.1 Million

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

THOMSON REUTERS

Challenger Gold Completes A$85m Raise and Reshapes Leadership for Next Growth Phase

Compass Pathways Grants New-Hire Inducement Equity Awards at USD 11.25 Per Share

Compass Pathways Announces New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Compass Pathways Plc Files for Mixed Shelf Offering; Size not Disclosed - SEC Filing

THOMSON REUTERS

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS), Geron (GERN) and Azenta (AZTA)

Compass Pathways PLC Reports Results for the Quarter Ended June 30 - Earnings Summary

Compass Pathways Publishes Investor Presentation on Comp360 Psilocybin Program, FDA Filing Progress and Launch Plans

Compass Pathways' Q2 Loss Widens on Commercial Readiness Activity Costs

Compass Pathways Q2 EPS $(1.88) Misses $(0.37) Estimate

Benzinga Earnings

Compass Pathways Q2 EPS USD -1.88

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/PSIL/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.32,"timestamp":1789588800000,"preClose":24.5,"halted":0,"volume":25811,"hourTrading":{"tag":"盘后","latestPrice":23.97,"preClose":24.32,"latestTime":"19:56 EDT","volume":1038,"amount":24919.4073,"timestamp":1789603002316,"change":-0.35,"changeRate":-0.014391,"amplitude":0.014391},"delay":0,"changeRate":-0.007346938775510192,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"Closed","change":-0.18,"latestTime":"09-16 16:00:00 EDT","open":24.66,"high":24.66,"low":24.14,"amount":629579.3309,"amplitude":0.021224,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":24.5,"sharesOutstanding":1184976,"nav":24.374,"aum":56546897.05,"dividendRate":0.070115,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":25.06,"preClose":24.5,"latestTime":"08:44 EDT","volume":39,"amount":972.7199820000001,"timestamp":1789562657590,"change":0.56,"changeRate":0.022857,"amplitude":0.039592},"postHourTrading":{"tag":"盘后","latestPrice":23.97,"preClose":24.32,"latestTime":"19:56 EDT","volume":1038,"amount":24919.4073,"timestamp":1789603002316,"change":-0.35,"changeRate":-0.014391,"amplitude":0.014391},"volumeRatio":0.538481,"impliedVol":0.5167,"impliedVolPercentile":0.8645},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.538481,"shares":2319976,"dividePrice":1.7052,"high":24.66,"amplitude":0.021224,"preClose":24.5,"low":24.14,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.32,"eps":0,"divideRate":0.070115,"volume":25811,"delay":0,"ttmEps":0,"open":24.66,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":25.21,"twentyDayClose":26.2,"sixtyDayClose":21.35},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657631659","title":"RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631659","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657631659?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:32","pubTimestamp":1786019564,"startTime":"0","endTime":"0","summary":"COMPASS Pathways (CMPS) has an average rating of buy and mean price target of $23.35, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657395516","title":"Praxis Precision Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657395516","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657395516?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:12","pubTimestamp":1786018371,"startTime":"0","endTime":"0","summary":"Praxis Precision Q2 net loss widens on higher expensesOverviewUS CNS drug developer's Q2 net loss widened yr/yr on higher operating expensesCompany ended Q2 with $1.4 bln in cash and investments, fund","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","VNDA","BK4007","IE0009355771.USD","PRAX","IE00BJT1NW94.SGD","BK4139","IE00BFTCPJ56.SGD","PSIL","BK4539","HRMY","LU0109394709.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IBRN","GHRS","LU0320765992.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663689","title":"Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663689","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663689?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:58","pubTimestamp":1786017486,"startTime":"0","endTime":"0","summary":"Ireland's GH Research Q2 net loss widens on higher R&D costsOverviewIreland biopharmaceutical firm's Q2 net loss widened yr/yr, with higher R&D and G&A expensesCompany's cash and marketable securities","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430MD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4007","LU0823416689.USD","LU0889565916.HKD","BK4539","CNTX","LU0154245673.USD","BK4139","LU0154245756.USD","IE00BN0W2V16.EUR","JAZZ","CMPS","LU0320765992.SGD","PSIL","BK4533","LU0109394709.USD","BK4532","GHRS","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657359246","title":"GH Research Plc Q2 EPS USD -0.23","url":"https://stock-news.laohu8.com/highlight/detail?id=2657359246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657359246?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:42","pubTimestamp":1786016572,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXPBJD44:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PSIL","GHRS","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657926633","title":"GH Research Says H1 Loss Widens as R&D Spending Rises on GH001 Clinical, Technical Development Work","url":"https://stock-news.laohu8.com/highlight/detail?id=2657926633","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657926633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:26","pubTimestamp":1786015613,"startTime":"0","endTime":"0","summary":"GH Research says H1 loss widens as R&D spending rises on GH001 clinical, technical development workGH Research posted a net loss of USD 34.11 million for the six months ended June 30, 2026, driven by ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL3lWYPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PSIL","GHRS","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657692633","title":"Scholar Rock Q2 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657692633","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657692633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:22","pubTimestamp":1786015339,"startTime":"0","endTime":"0","summary":"Scholar Rock Q2 net loss narrowsOverviewUS biopharmaceutical firm's Q2 net loss narrowed slightly yr/yr with no revenue recordedOperating expenses for Q2 fell, driven by reduced research and developme","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","IBRN","THNR","CMPS","BK4584","MNKD","BK4139","SRRK","BDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633319","title":"GH Research Publishes Corporate Presentation on Ultra-Rapid, Durable Remission Data for TRD Treatment GH001","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633319","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633319?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:19","pubTimestamp":1786015157,"startTime":"0","endTime":"0","summary":"GH Research publishes corporate presentation on ultra-rapid, durable remission data for TRD treatment GH001GH Research highlighted Phase 2b data for GH001, an inhaled mebufotenin candidate for treatme","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL1w2P6d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GHRS","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638668","title":"GH Research Q2 FY26 Net Loss Widens to $15.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638668","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638668?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:03","pubTimestamp":1786014184,"startTime":"0","endTime":"0","summary":"GH Research Q2 FY26 net loss widens to $15.1 millionGH Research posted a Q2 net loss of USD 15.1 million, or USD 0.23 per share, versus a USD 9.3 million loss a year earlier.R&D expenses climbed to US","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9LhCXq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GHRS","BK4007","BK4539","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657687402","title":"Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin","url":"https://stock-news.laohu8.com/highlight/detail?id=2657687402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657687402?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:42","pubTimestamp":1786012964,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44318H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657033945","title":"Challenger Gold Completes A$85m Raise and Reshapes Leadership for Next Growth Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2657033945","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657033945?lang=en_us&edition=fundamental","pubTime":"2026-08-06 09:59","pubTimestamp":1785981562,"startTime":"0","endTime":"0","summary":"Challenger Exploration Limited ( ($AU:CEL) ) has provided an update. Challenger Gold Limited has completed an A$85 million capital raising, includi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/challenger-gold-completes-a85m-raise-and-reshapes-leadership-for-next-growth-phase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/challenger-gold-completes-a85m-raise-and-reshapes-leadership-for-next-growth-phase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGUmain","GLD","GDX","SGCmain","IAU","NUGT","PSIL","518880","159934","DUST","GCmain","MGCmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571589","title":"Compass Pathways Grants New-Hire Inducement Equity Awards at USD 11.25 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571589","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571589?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:48","pubTimestamp":1785966539,"startTime":"0","endTime":"0","summary":"Compass Pathways grants new-hire inducement equity awards at USD 11.25 per shareCompass Pathways granted equity awards to 14 newly hired non-executive employees on Aug. 3, 2026 under its 2026 Induceme","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDLbD8XbV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657738605","title":"Compass Pathways Announces New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657738605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657738605?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:30","pubTimestamp":1785961801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUAMJ72R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657578488","title":"Compass Pathways Plc Files for Mixed Shelf Offering; Size not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2657578488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657578488?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:23","pubTimestamp":1785961439,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4421TK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657152527","title":"Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657152527","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657152527?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:01","pubTimestamp":1785960060,"startTime":"0","endTime":"0","summary":"Presented positive Phase 2 results for silevertinib in frontline patients with non-classical EGFRm NSCLC at the 2026 ASCO Annual Meeting, including that no patients developed de novo brain metastases ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339642/0/en/Black-Diamond-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC","BK4139","BDTX","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657522320","title":"Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS), Geron (GERN) and Azenta (AZTA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657522320","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657522320?lang=en_us&edition=fundamental","pubTime":"2026-08-06 02:50","pubTimestamp":1785955808,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on COMPASS Pathways (CMPS), Geron (GERN) and Azenta (AZTA). COMPASS ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compass-pathways-cmps-geron-gern-and-azenta-azta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compass-pathways-cmps-geron-gern-and-azenta-azta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065732104.USD","AZTA","BK4121","BK4588","LU1169589451.USD","LU0012050646.USD","BK4585","GERN","BK4581","LU0128526141.USD","LU0106261612.USD","HCSG","BK4137","IE00B7SZL793.SGD","IE00B66KJ199.SGD","IE0031619046.USD","LU0029874061.USD","PSIL","XLV","LU1169590202.USD","BK4139","IE00B19Z4B17.USD","LABU","CMPS","BK4147","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657540547","title":"Compass Pathways PLC Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657540547","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657540547?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:32","pubTimestamp":1785936746,"startTime":"0","endTime":"0","summary":"Compass Pathways PLC reports results for the quarter ended June 30 - Earnings SummaryCompass Pathways PLCCMPS.OQreported a quarterly adjusted loss of $1.88 per share for the quarter ended June 30, low","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N44224E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657544828","title":"Compass Pathways Publishes Investor Presentation on Comp360 Psilocybin Program, FDA Filing Progress and Launch Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2657544828","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657544828?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:07","pubTimestamp":1785931637,"startTime":"0","endTime":"0","summary":"Compass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plansCompass Pathways outlined plans to file a rolling NDA for COMP360 psilocybin in trea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL9WMrTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657545831","title":"Compass Pathways' Q2 Loss Widens on Commercial Readiness Activity Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657545831","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657545831?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:45","pubTimestamp":1785926714,"startTime":"0","endTime":"0","summary":"Compass Pathways' Q2 loss widens on commercial readiness activity costsOverviewUK mental health biotech's Q2 operating income missed analyst estimatesNet loss widened yr/yr, mainly due to non-cash war","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505868.SGD","LU0575583348.USD","LU1273509221.SGD","LU0203345920.USD","LU1863844749.USD","CMPS","ACAD","LU1989772923.USD","LIVN","LU0096364046.USD","SG9999001176.USD","LU2065170008.USD","LU1481600234.SGD","LFSC","AZN.UK","LU0432979614.USD","LU2596442595.SGD","LU1880407215.USD","LU1057294990.SGD","LU2539964713.USD","LU0306807586.USD","03165","LU2279689827.SGD","LU0211326839.USD","LU1196032939.SGD","FTXH","LU0985481810.HKD","LU1046234339.USD","LU2089284900.SGD","LU0496365809.HKD","LU2065171311.SGD","LU2125154935.USD","IHE","LU0757432116.USD","LU1291159041.SGD","LU0526926950.USD","LU1670710588.SGD","LU1983299246.USD","LU1153585028.USD","LU1585245621.USD","SGXZ57979304.SGD","LU0997586432.USD","BMY","LU0310799852.SGD","LU1718418525.SGD","SG9999013999.USD","BK4007","LU0266013472.USD","LU2237443978.SGD","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657254330","title":"Compass Pathways Q2 EPS $(1.88) Misses $(0.37) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657254330","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657254330?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:33","pubTimestamp":1785925989,"startTime":"0","endTime":"0","summary":"Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(1.88) per share which missed the analyst consensus estimate of $(0.37) by 408.11 percent. This is a 358.54 percent decrease over losses of $(0.41) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60941435/compass-pathways-q2-eps-1-88-misses-0-37-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657548774","title":"Compass Pathways Q2 EPS USD -1.88","url":"https://stock-news.laohu8.com/highlight/detail?id=2657548774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657548774?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:30","pubTimestamp":1785925800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLXD2DKG4:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}